eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2022
vol. 18
 
Share:
Share:
more
 
 
abstract:
Original paper

Mid-term outcomes of patients with Lotus and Evolut transcatheter valves

Petr Hájek
1
,
Eva Polaková
1
,
Radka Adlová
1
,
Martin Horváth
1
,
Eva Hansvenclová
1
,
Monika Pecková
2
,
Josef Veselka
1

1.
Department of Cardiology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic
2.
Institute of Applied Mathematics and Information Technologies, Faculty of Science, Charles University, Prague, Czech Republic
Adv Interv Cardiol 2022; 18, 2 (68): 146–153
Online publish date: 2022/08/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Summary

Long-term data on Lotus® (Boston Scientific, USA) transcatheter aortic valve prostheses are lacking. Our study suggests that higher cardiovascular mortality rates during mid-term follow-up were associated with Lotus compared with Evolut valves. Higher gradients on the Lotus valves at the end of follow-up suggest the possibility of accelerated prosthesis degeneration.

Introduction

The Lotus® valve (Boston Scientific, USA), designed for transcatheter aortic valve implantation (TAVI), was promising because of the repositionable and fully retrievable prosthesis with excellent procedural [1, 2] and 1-year follow-up results [2, 3]. The Lotus valve also included an adaptive seal to effectively minimize paravalvular leak (PVL) [4] and thus enabled TAVI also in complex anatomies such as stenosis of bicuspid aortic valve [5–7]. However, long-term data on Lotus are lacking compared with results for other currently used TAVI valves [8–10]. With the extension of TAVI indications to younger, lower-risk patients [11], data on long-term transcatheter valve durability are essential [12]. Although the Lotus valve was recalled in 2020 [13, 14] and is not available for clinical use, thousands of valves were implanted over the last decade.

Aim

We evaluated the mid-term outcomes of patients with Lotus and compared them with those of patients with Evolut R® valves (Medtronic, USA).

Material and methods

Design

We conducted a single-centre, retrospective, observational study comparing outcomes of patients with severe aortic stenosis (AS), who underwent TAVI with Lotus or Evolut R valves. The study was approved by a multicentre Ethics Committee and was conducted in accordance with the principles of the Declaration of Helsinki.

Patients and procedures

A total of 197 consecutive patients with severe AS, who underwent TAVI between August 2015 and January 2020, were enrolled in this study. Patients were either admitted haemodynamically stable for planned diagnostic evaluation or admitted acutely with decompensated heart failure. Diagnosis of severe AS was made according to echocardiographic criteria. The indication for TAVI was established as a consensus of members of the heart team. All TAVI procedures were performed by highly experienced interventional cardiologists in a single tertiary centre. Clinical, demographic, and echocardiographic data were recorded at baseline and during follow-up. Patients had...


View full text...
keywords:

outcome, transcatheter aortic valve implantation, Lotus transcatheter valve

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.